| __timestamp | Agios Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 5114000 |
| Thursday, January 1, 2015 | 35992000 | 13403000 |
| Friday, January 1, 2016 | 50714000 | 31056000 |
| Sunday, January 1, 2017 | 71124000 | 35845000 |
| Monday, January 1, 2018 | 114145000 | 48294000 |
| Tuesday, January 1, 2019 | 132034000 | 63488000 |
| Wednesday, January 1, 2020 | 149070000 | 88208000 |
| Friday, January 1, 2021 | 121445000 | 102802000 |
| Saturday, January 1, 2022 | 121673000 | 102464000 |
| Sunday, January 1, 2023 | 119903000 | 76162000 |
| Monday, January 1, 2024 | 156784000 | 72977000 |
Data in motion
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: Agios Pharmaceuticals, Inc. and CRISPR Therapeutics AG, from 2014 to 2023.
Agios Pharmaceuticals has shown a steady increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. This growth reflects their aggressive expansion and investment in administrative capabilities.
CRISPR Therapeutics, known for its groundbreaking gene-editing technology, also saw a significant increase in SG&A expenses, with a 1,900% surge by 2021. However, a notable decline in 2023 suggests a strategic shift or cost optimization.
These trends highlight the contrasting strategies of these biotech giants, offering insights into their operational priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.